According to a recent LinkedIn post from Cleerly, the company plans to showcase its AI-powered cardiac imaging platform at the American College of Cardiology’s ACC.26 meeting in New Orleans from March 28 to 30. The post highlights that Cleerly will demonstrate how its technology augments coronary computed tomography angiography, or CCTA, by providing quantitative insights into the root causes of coronary artery disease.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post emphasizes advanced plaque analysis capabilities that generate 3D models of coronary arteries and color-code different plaque types to support clinical decision-making. For investors, this presence at a major cardiology conference may signal efforts to drive broader clinical adoption, strengthen relationships with cardiology stakeholders, and differentiate its platform in the competitive cardiac imaging and AI diagnostics landscape.
If Cleerly can convert conference visibility into new clinical deployments or partnerships with health systems and cardiovascular practices, it could support revenue growth and recurring software usage over time. The focus on AI-enabled, quantitative assessment of coronary plaque also aligns with industry trends toward more precise risk stratification and value-based care, which may enhance the company’s positioning relative to traditional imaging workflows and competing digital health tools.